Effect of Hyperbaric Oxygen Therapy(HBOT) on Patients With Sudden Sensorineural Hearing Loss(SSNHL) and Coagulation Function
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorSun Yuting
About this trial
The objective of this observational study was to understand the effect of HBO on patients with SSNHL and its association with coagulation function and prognosis.
The main question it aims to answer is whether HBO therapy can improve outcomes and coagulation function in patients with SSNHL.
The prognosis of SSNHL patients receiving HBO and SSNHL patients not receiving HBO were compared
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Meet the diagnostic criteria for sudden deafness in the American Academy of Otolaryngology Head and Neck Surgery 2019 Clinical Practice Guidelines for Sudden Deafness;
Aged 18-75 years old;
Patients with unilateral sudden deafness for the first time, and the onset time is less than 2 weeks.
Disqualifiers
Patients with other ear diseases, such as auditory trauma, barotrauma, retrocochlear disease, bilateral hearing loss, history of chronic otitis media in the same ear, and history of surgery in the same ear;
Patients with serious primary diseases such as heart, liver, kidney dysfunction and hematopoietic system diseases;
Pregnant and nursing patients;
Accompanied by serious mental illness;
Trial population
From January 2022 to September 2024, in Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Otolaryngology Hospital Affiliated to Fudan University, Xinhua Hospital affiliated to Shanghai Jiao Tong University or Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, treating patients with sudden sensorineural deafness.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Hyperbaric oxygen treatment
Other interventionHBO therapy is the process of inhaling 100% pure oxygen in an environment above one atmosphere (pressure range: 2.0-3.0 absolute atmospheres) to treat a disease.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Hearing recovery rate
The rate of hearing recovery in patients with all levels of hearing loss at completion of treatment and at 3 months after termination of treatment was assessed according to the WHO Hearing Loss Rating Criteria 2021 to determine the success of treatment.
Time frame
From onset to 3 months after treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Sun Yuting
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: